JP7312698B2 - オピオイド過剰摂取を処置するための組成物および方法 - Google Patents

オピオイド過剰摂取を処置するための組成物および方法 Download PDF

Info

Publication number
JP7312698B2
JP7312698B2 JP2019526565A JP2019526565A JP7312698B2 JP 7312698 B2 JP7312698 B2 JP 7312698B2 JP 2019526565 A JP2019526565 A JP 2019526565A JP 2019526565 A JP2019526565 A JP 2019526565A JP 7312698 B2 JP7312698 B2 JP 7312698B2
Authority
JP
Japan
Prior art keywords
nalmefene
patient
pharmaceutical formulation
opioid
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534315A (ja
JP2019534315A5 (cg-RX-API-DMAC10.html
Inventor
ロジャー クリスタル
エドワード ティー． マッジオ
Original Assignee
オーピアント ファーマシューティカルズ， インコーポレイテッド
イージス セラピューティクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7312698(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オーピアント ファーマシューティカルズ， インコーポレイテッド, イージス セラピューティクス リミテッド ライアビリティ カンパニー filed Critical オーピアント ファーマシューティカルズ， インコーポレイテッド
Publication of JP2019534315A publication Critical patent/JP2019534315A/ja
Publication of JP2019534315A5 publication Critical patent/JP2019534315A5/ja
Priority to JP2023112864A priority Critical patent/JP7730443B2/ja
Application granted granted Critical
Publication of JP7312698B2 publication Critical patent/JP7312698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019526565A 2016-11-18 2017-11-09 オピオイド過剰摂取を処置するための組成物および方法 Active JP7312698B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023112864A JP7730443B2 (ja) 2016-11-18 2023-07-10 オピオイド過剰摂取を処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424378P 2016-11-18 2016-11-18
US62/424,378 2016-11-18
PCT/US2017/060964 WO2018093666A1 (en) 2016-11-18 2017-11-09 Compositions and methods for the treatment of opioid overdose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023112864A Division JP7730443B2 (ja) 2016-11-18 2023-07-10 オピオイド過剰摂取を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019534315A JP2019534315A (ja) 2019-11-28
JP2019534315A5 JP2019534315A5 (cg-RX-API-DMAC10.html) 2020-12-17
JP7312698B2 true JP7312698B2 (ja) 2023-07-21

Family

ID=62146061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019526565A Active JP7312698B2 (ja) 2016-11-18 2017-11-09 オピオイド過剰摂取を処置するための組成物および方法
JP2023112864A Active JP7730443B2 (ja) 2016-11-18 2023-07-10 オピオイド過剰摂取を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023112864A Active JP7730443B2 (ja) 2016-11-18 2023-07-10 オピオイド過剰摂取を処置するための組成物および方法

Country Status (9)

Country Link
US (3) US11458091B2 (cg-RX-API-DMAC10.html)
EP (1) EP3541386A4 (cg-RX-API-DMAC10.html)
JP (2) JP7312698B2 (cg-RX-API-DMAC10.html)
CN (1) CN110139651A (cg-RX-API-DMAC10.html)
AU (2) AU2017360910B2 (cg-RX-API-DMAC10.html)
CA (1) CA3044221A1 (cg-RX-API-DMAC10.html)
IL (2) IL312012A (cg-RX-API-DMAC10.html)
RU (1) RU2769397C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018093666A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12290596B2 (en) 2021-08-04 2025-05-06 Indivior Uk Limited Compositions and methods for the treatment of opioid overdose

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
WO2019231993A1 (en) * 2018-06-01 2019-12-05 Purdue Pharma L.P. Compositions and methods for opioid overdose rescue
US11865112B2 (en) 2018-11-06 2024-01-09 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US20210401827A1 (en) * 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
CA3134943A1 (en) 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CA3167312A1 (en) * 2020-02-07 2021-08-12 Stephen J. Lewis Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
CN115515621A (zh) * 2020-05-04 2022-12-23 安福星制药公司 胆汁酸及其盐作为药物的经鼻递送的增强剂的安全用途
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
US20220111162A1 (en) * 2020-07-29 2022-04-14 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient
EP4284506A4 (en) * 2021-02-01 2024-12-25 Clear Scientific, Inc. SEQUESTRATION COMPOUNDS FOR THE TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF
US20220387407A1 (en) * 2021-02-08 2022-12-08 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2024010379A1 (ko) * 2022-07-05 2024-01-11 주식회사 지투지바이오 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2024222920A1 (zh) * 2023-04-28 2024-10-31 成都苑东生物制药股份有限公司 一种用于鼻内给药的药物制剂及其制备方法
WO2025255416A1 (en) * 2024-06-05 2025-12-11 TMTRx, Inc. Fentanyl and fentanyl analogue overdose reversal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634062A (zh) 2004-10-13 2005-07-06 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
JP2011516425A (ja) 2008-03-28 2011-05-26 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
JP2014519525A (ja) 2011-06-14 2014-08-14 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4880813A (en) 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US5069895A (en) 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
EP0444778A1 (en) 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
EP1423116A1 (en) 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20070212307A1 (en) 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
WO2008095086A2 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
JP2010537990A (ja) 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
WO2009128474A1 (ja) 2008-04-16 2009-10-22 財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
ES2686299T3 (es) 2010-10-29 2018-10-17 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina B12
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
EP3057596A4 (en) 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
AU2015228541B2 (en) * 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US20160008277A1 (en) 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
NZ750067A (en) * 2016-06-24 2025-11-28 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
WO2018093666A1 (en) 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
CN106361700A (zh) 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
US20210220346A1 (en) 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
US20210401827A1 (en) 2018-11-07 2021-12-30 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
WO2020132263A1 (en) 2018-12-20 2020-06-25 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) 2018-12-20 2020-12-17 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634062A (zh) 2004-10-13 2005-07-06 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
JP2011516425A (ja) 2008-03-28 2011-05-26 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
JP2014519525A (ja) 2011-06-14 2014-08-14 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12290596B2 (en) 2021-08-04 2025-05-06 Indivior Uk Limited Compositions and methods for the treatment of opioid overdose

Also Published As

Publication number Publication date
US20200060967A1 (en) 2020-02-27
IL266674B1 (en) 2024-05-01
IL266674A (en) 2019-07-31
AU2017360910B2 (en) 2023-11-23
WO2018093666A1 (en) 2018-05-24
IL266674B2 (en) 2024-09-01
IL312012A (en) 2024-06-01
EP3541386A4 (en) 2020-05-27
CN110139651A (zh) 2019-08-16
AU2024201047A1 (en) 2024-03-14
US20220387306A1 (en) 2022-12-08
JP2023140359A (ja) 2023-10-04
US20250127712A1 (en) 2025-04-24
RU2019118465A3 (cg-RX-API-DMAC10.html) 2021-03-04
JP7730443B2 (ja) 2025-08-28
AU2017360910A1 (en) 2019-05-30
EP3541386A1 (en) 2019-09-25
CA3044221A1 (en) 2018-05-24
JP2019534315A (ja) 2019-11-28
RU2019118465A (ru) 2020-12-18
US11458091B2 (en) 2022-10-04
RU2769397C2 (ru) 2022-03-31

Similar Documents

Publication Publication Date Title
JP7730443B2 (ja) オピオイド過剰摂取を処置するための組成物および方法
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20210077382A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
JP2021046408A (ja) 経鼻薬物製品およびその使用方法
US20260021038A1 (en) Compositions and Methods for the Treatment of Opioid Overdose
US20240197719A1 (en) Formulations and methods for the prevention of opioid overdose
EP3876937A1 (en) Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
JP2024164155A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
US20240408004A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20240408003A1 (en) Compositions, devices and methods for the treatment of alcohol use disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230710

R150 Certificate of patent or registration of utility model

Ref document number: 7312698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250